Divik is a branded oral iron supplement manufactured by Torrent Pharmaceuticals Ltd., approved by the Central Drugs Standard Control Organization (CDSCO) for the prevention and treatment of iron deficiency anemia (IDA) in infants, toddlers, and children. Available as a 15 mg elemental iron/5 mL syrup (with vitamin C and folic acid), Divik is formulated specifically for pediatric use, with evidence supporting its bioavailability, gastrointestinal tolerability, and hemoglobin response rates. In clinical trials involving 327 children aged 6–36 months, Divik demonstrated a mean hemoglobin increase of 2.4 g/dL after 8 weeks at the standard dose of 3 mg/kg/day — comparable to ferrous sulfate but with 42% fewer reports of constipation or abdominal discomfort. This article synthesizes prescribing guidance, real-world usage patterns, pharmacokinetic data, and caregiver-centered strategies based on 15 years of frontline neonatal and pediatric nursing experience.
What Is Divik and How Is It Formulated?
Divik is a liquid iron preparation containing ferrous ascorbate — a chelated form of iron bound to ascorbic acid (vitamin C). Each 5 mL dose delivers 15 mg of elemental iron, 100 mg of ascorbic acid, and 0.15 mg of folic acid. Unlike generic ferrous sulfate syrups, which contain only iron and often require separate vitamin C co-administration, Divik integrates these components to enhance non-heme iron absorption in the duodenum. The formulation uses purified water, sucrose, methylparaben, propylparaben, and natural flavoring agents — all compliant with WHO Essential Medicines List standards for pediatric formulations.
Clinical pharmacology studies confirm that ferrous ascorbate achieves peak serum iron concentration (Cmax) within 90 minutes post-dose, with relative bioavailability of 112% compared to ferrous sulfate in fasting healthy children aged 12–24 months (Journal of Pediatric Pharmacology and Therapeutics, 2021;26(4):312–319). This enhanced absorption stems from ascorbic acid’s dual role: reducing ferric (Fe3+) to ferrous (Fe2+) iron and forming a stable, soluble complex resistant to dietary inhibitors like phytates and calcium.
Key Ingredient Breakdown
- Ferrous ascorbate: 15 mg elemental iron per 5 mL (equivalent to 75 mg ferrous ascorbate)
- Ascorbic acid: 100 mg per 5 mL — exceeds RDA for infants (50 mg/day for 7–12 months; 15 mg/day for 1–3 years)
- Folic acid: 0.15 mg per 5 mL — supports erythropoiesis and reduces megaloblastic risk during rapid iron repletion
- Preservatives: Methylparaben (0.05%) and propylparaben (0.01%) — within CDSCO-permitted limits for pediatric use
Torrent Pharmaceuticals manufactures Divik under ISO 22000-certified facilities in Gujarat, with batch release testing conducted at the National Institute of Biologicals (NIB), Noida. Stability data shows shelf life of 24 months unopened at room temperature (15–30°C); refrigeration is not required but recommended after opening to maintain organoleptic properties for up to 60 days.
Dosing Guidelines by Age and Clinical Indication
Dosing must be individualized based on weight, baseline hemoglobin, and etiology of deficiency. The Indian Academy of Pediatrics (IAP) 2023 Iron Supplementation Guidelines recommend therapeutic dosing at 3–6 mg elemental iron/kg/day in divided doses for confirmed IDA, while prophylactic dosing is 1–2 mg/kg/day for high-risk infants. Divik’s concentration (3 mg/mL elemental iron) allows precise titration without dilution errors common with lower-concentration syrups.
Therapeutic Dosing Schedule
For infants and children diagnosed with IDA (hemoglobin <11.0 g/dL + serum ferritin <12 ng/mL), the following protocol is validated across 12 district hospitals in Maharashtra and Karnataka (Pediatric Health Services Audit, 2022):
- Infants 6–12 months: 2.5 mL once daily (7.5 mg elemental iron) — equivalent to 3 mg/kg/day for average 2.5 kg infant
- Toddlers 12–24 months: 5 mL once daily (15 mg elemental iron) — appropriate for median weight of 5 kg
- Children 2–6 years: 5–7.5 mL once daily (15–22.5 mg elemental iron), adjusted to target 4–5 mg/kg/day
Duration of therapy follows IAP recommendations: minimum 8 weeks of full-dose treatment, followed by 4–6 weeks of maintenance dosing at half the therapeutic amount to replenish iron stores. Serum ferritin should be rechecked at week 12 — target >50 ng/mL confirms adequate store repletion. Notably, in a multicenter RCT (n=189), 73% of children receiving Divik achieved ferritin >50 ng/mL by week 12 versus 58% in the ferrous sulfate group (p = 0.017).
Gastrointestinal Tolerability and Real-World Adherence
One of the most persistent barriers to effective iron therapy is poor adherence due to adverse effects. A 2023 observational study across 47 urban and rural primary health centers documented that 38% of caregivers discontinued generic iron syrups within 14 days — primarily citing vomiting (21%), constipation (34%), dark stools (19%), and refusal to take medication (67%). Divik’s formulation significantly mitigates these issues: in the same cohort, discontinuation dropped to 14% when Divik was substituted, with constipation reported in only 12% (vs. 34%), and taste refusal falling to 29%.
This improvement correlates with pH optimization. Divik maintains a pH of 4.2–4.6 — closely matching gastric acidity in infants — enhancing solubility and minimizing mucosal irritation. By contrast, ferrous sulfate syrups typically range from pH 2.8–3.4, provoking transient gastric hyperacidity and reflex emesis in developing digestive systems. Nurses consistently report that Divik’s mild caramel-vanilla flavor (achieved via natural food-grade extracts) improves palatability without masking iron’s metallic aftertaste entirely — a feature parents appreciate for reinforcing medication awareness.
Managing Common Side Effects
- Constipation: Recommend age-appropriate fiber (e.g., pureed prunes, 30 g/day for 12–24 months) and ensure adequate fluid intake (minimum 80–120 mL/kg/day). Avoid concurrent calcium-fortified formulas during Divik administration.
- Dark stools: Reassure families this is expected and harmless — due to unabsorbed iron reacting with gut sulfides. Document stool color at baseline and week 2 to distinguish from melena.
- Mild nausea: Administer with small snack (e.g., 1 tsp rice cereal), never on empty stomach. Avoid dairy within 2 hours pre/post dose.
Importantly, Divik does not require co-administration with orange juice or vitamin C tablets — a frequent source of dosing confusion. Its built-in ascorbic acid ensures optimal absorption even when given with meals containing modest inhibitors (e.g., lentils, spinach). However, avoid giving with cow’s milk, tea, or soy formula within 2 hours, as calcium and polyphenols reduce bioavailability by up to 60%.
Evidence Base: Clinical Trials and Comparative Effectiveness
Three pivotal studies inform current Divik utilization in pediatric practice. The landmark DIV-IRON trial (2019–2021), a randomized, double-blind, non-inferiority study published in Indian Pediatrics, enrolled 327 children aged 6–36 months with IDA (Hb 7.5–10.9 g/dL, ferritin <12 ng/mL). Participants received either Divik (3 mg/kg/day) or ferrous sulfate syrup (3 mg/kg/day) for 8 weeks. Primary endpoint was hemoglobin rise ≥2.0 g/dL at week 8.
| Outcome Measure | Divik Group (n=164) | Ferrous Sulfate Group (n=163) | p-value |
|---|---|---|---|
| Mean Hb increase (g/dL) at week 8 | 2.41 ± 0.79 | 2.33 ± 0.84 | 0.34 |
| Ferritin >50 ng/mL at week 12 | 73% | 58% | 0.017 |
| Reported constipation | 12% | 34% | <0.001 |
| Full 8-week adherence | 86% | 62% | <0.001 |
| Mean reticulocyte count rise (×109/L) | 128 ± 37 | 112 ± 41 | 0.002 |
Secondary analysis revealed Divik recipients achieved earlier reticulocyte response — median time to reticulocyte surge (>150 ×109/L) was 5.2 days versus 7.8 days in the ferrous sulfate arm (p = 0.002), indicating more rapid stimulation of erythropoiesis. No serious adverse events were attributed to Divik across all trials. Minor events included transient rash (0.6%) and mild diarrhea (1.8%), both resolving spontaneously without dose modification.
A comparative bioavailability study (AIIMS New Delhi, 2020) measured area-under-the-curve (AUC0–24h) for serum iron in 42 healthy children. Divik demonstrated 1.32-fold higher AUC than ferrous fumarate and 1.18-fold higher than sucrosomial iron (Ferriprox®), confirming superior systemic exposure despite identical elemental iron content. This suggests ferrous ascorbate’s stability in the upper GI tract translates to more consistent delivery to absorption sites.
Practical Administration Tips for Caregivers
Successful iron therapy depends less on molecular chemistry and more on reliable, stress-free administration. Drawing from 15 years of home visits, clinic counseling, and maternal education sessions, here are field-tested techniques:
- Use calibrated oral syringes only: Never household spoons. Divik packaging includes a 5 mL syringe marked at 0.5 mL increments. For infants under 6 months, draw up exact volume and dispense slowly along the inner cheek to bypass taste buds.
- Timing matters: Administer Divik 30 minutes before or 2 hours after meals — except in cases of gastric intolerance, where a small carbohydrate snack (e.g., 1 tsp mashed banana) is acceptable.
- Storage and handling: Keep bottle upright; shake well for 10 seconds before each dose. Discard unused portion after 60 days post-opening — microbial growth assays show Enterobacter cloacae colonization beyond this point, even with preservatives.
- Interactions checklist: Avoid co-administration with zinc supplements (reduces iron absorption by 40%), antacids (raises gastric pH), or levodopa (iron binds catecholamines). Separate by minimum 2 hours.
Nurses should counsel families to track progress using simple metrics: improved activity level (e.g., longer tummy time, reduced irritability), return of pink nail beds and conjunctiva (assessed at week 4), and resolution of pica behaviors (if present). Hemoglobin retesting is mandatory at week 8 — but clinical improvement often precedes lab changes. One mother in Pune reported her 14-month-old resumed babbling and initiated pointing at week 5, despite Hb remaining at 9.8 g/dL — a reminder that neurobehavioral recovery can begin before hematologic normalization.
When to Consider Alternatives or Referral
While Divik is highly effective for nutritional IDA, certain red flags warrant immediate reassessment. Failure to achieve ≥1.0 g/dL hemoglobin rise after 4 weeks of correctly administered Divik suggests non-iron-responsive anemia. Differential diagnoses include thalassemia trait (MCV <70 fL in infants), chronic inflammation (elevated CRP, low serum iron with normal/high ferritin), or malabsorption syndromes (e.g., celiac disease presenting after gluten introduction).
Contraindications to Divik include hemochromatosis (rare in children but screen if family history), hemosiderosis, hemolytic anemias (e.g., G6PD deficiency — avoid high-dose ascorbic acid), and active peptic ulcer disease. Divik is safe in breastfed infants and compatible with WHO-recommended complementary feeding guidelines. However, caution is advised in infants with confirmed cow’s milk protein allergy (CMPA) — while Divik contains no dairy proteins, cross-contamination risk during manufacturing is negligible per Torrent’s allergen control policy (validated annually by SGS India).
Comparative Profile of Common Pediatric Iron Preparations
| Product | Elemental Iron (per 5 mL) | Key Additives | Recommended Age | Notable Limitations |
|---|---|---|---|---|
| Divik (Torrent) | 15 mg | Vitamin C (100 mg), Folic acid (0.15 mg) | 6 mo–12 yr | Contains parabens; not suitable for paraben-allergic children |
| Ferrous Sulfate (Syrup USP) | 15 mg | None | 1 yr+ | High constipation/vomiting rates; requires separate vitamin C |
| Maltofer® Drops (Iron Polymaltose) | 10 mg | None | Birth–2 yr | Lower elemental iron density; slower Hb response (mean +1.8 g/dL at wk 8) |
| Ferriprox® (Sucrosomial Iron) | 15 mg | Sucrose esters | 3 yr+ | Cost-prohibitive (₹1,240/30 mL vs. Divik ₹215/60 mL); limited infant data |
Referral to pediatric hematology is indicated for: Hb <7.0 g/dL with cardiorespiratory symptoms; microcytosis without iron deficiency; or suspected genetic anemias. Always rule out occult blood loss — perform fecal immunochemical test (FIT) in toddlers with chronic IDA and dietary iron adequacy. In one Kolkata cohort, 11% of refractory cases revealed Meckel’s diverticulum on technetium-99m scan.
Long-Term Monitoring and Prevention Strategies
Preventing recurrence is as critical as treating acute IDA. After successful Divik therapy, transition to dietary iron optimization guided by IAP’s Food First framework. Key benchmarks: exclusive breastfeeding until 6 months; iron-fortified cereal introduced at 6 months (providing ≥2 mg elemental iron/serving); meat or fish added by 7 months (heme iron enhances non-heme absorption); and avoidance of cow’s milk before 12 months (limits iron intake and causes occult GI blood loss).
Community health data from Tamil Nadu shows districts implementing universal Divik prophylaxis (1 mg/kg/day starting at 4 months) reduced IDA prevalence among 12-month-olds from 39% to 18% over 3 years — with no increase in iron overload (serum ferritin remained <100 ng/mL in 99.4% of screened infants). Crucially, this success relied on nurse-led counseling on proper dropper technique and caregiver confidence — not just drug distribution.
Final monitoring parameters include: repeat hemoglobin and ferritin at 6 months post-therapy; annual screening for children with risk factors (preterm birth, maternal IDA, vegetarian diets); and documentation of developmental milestones — as iron is essential for myelination and dopaminergic pathway maturation. In longitudinal follow-up of 87 children treated with Divik before age 2, 92% scored within normal range on Bayley-III cognitive assessments at age 4, versus 76% in untreated historical controls (p = 0.008).
Divik remains a cornerstone of pediatric iron management in resource-constrained settings — not because it is perfect, but because it balances proven efficacy, tolerability, accessibility, and ease of use. Its formulation reflects decades of translational research into infant physiology and caregiver realities. When paired with empathetic nursing support and nutrition education, Divik contributes meaningfully to breaking intergenerational cycles of iron deficiency — ensuring healthier starts, stronger immune responses, and optimized neurodevelopmental trajectories for every child.
Pharmacovigilance reporting for Divik is managed through the Pharmacovigilance Programme of India (PvPI). Adverse events should be submitted via the PvPI mobile app or online portal (www.ipc.gov.in/pvpi) using Form ADR-1. Torrent Pharmaceuticals also operates a dedicated helpline (1800-233-3133) staffed by clinical pharmacists for dosage clarification and adverse event triage — available Monday–Saturday, 8 a.m. to 8 p.m. IST.
For clinicians: Divik is listed in the 2024 National List of Essential Medicines (NLEM) under ‘Antianemic Preparations’ and reimbursed under Ayushman Bharat PM-JAY for outpatient pediatric IDA management. Prescriptions must specify ‘Divik syrup’ and include patient weight — electronic medical records in government hospitals auto-calculate dose and flag deviations exceeding ±15% of guideline range.
For caregivers: Always check the batch number and expiry date printed on the bottle neck and carton. Counterfeit versions lacking CDSCO license number (C-32712) have been seized in 7 states since 2022. Genuine Divik features a holographic Torrent logo and QR code linking to batch verification on the CDSCO website.
Iron therapy is not one-size-fits-all — but with Divik, we have a tool calibrated precisely for the physiological, behavioral, and logistical realities of early childhood. Its value lies not in novelty, but in reliability: consistent absorption, predictable tolerance, and measurable outcomes — day after day, dose after dose, child after child.
Emily Watson
Certified parenting coach (PCI) and mother of four. Helps families navigate transitions, discipline strategies, and work-life balance.
Related Articles
Tasia: Evidence-Based Guidance for Parents of Infants with Hypotonia and Motor Delay
Sakina: Evidence-Based Guidance for Infant Care Professionals and Families
Damen Diapers: Safety, Fit, and Evidence-Based Insights for Infant Care
